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Poster Session I S215Methods: We conducted a retrospective case control study. Blood
counts and progenitor cell yields from AA (N5 22) and Hispanic
(N5 12) normal donors were compared with Caucasian normal do-
nors (N5 34). Donor factors known to affect progenitor cell yields
were matched between groups for age, sex and weight. Donors gen-
erally received G-CSF (10mcg/kg daily) for 5 days. Twenty liter
aphereses were performed beginning on day 5.
Results: Counts from peripheral blood and aphereses products are
presented in the table.
Conclusion: These data suggest that despite lower baseline leuko-
cyte and neutrophil counts that responses to G-CSF and progenitor
cell yields after G-CSF in healthy AA donors are at least as good as
Caucasian and Hispanic donors.
AfricanParameter (mean/median) American Hispanic Caucasian p-value*Donor characteristicsAge 42/44 41.4/41 43.4/44 0.70Gender 8 M/14F 6 M/6F 14 M/20FWeight 89.2/86.1 77.5/77.2 80.9/81.5 0.23Baseline Blood CountsWBC count x10^3/uL 6.1/5.9 7.3/7.2 7.1/7.15 0.03Neutrophil count x 10^3/
uL3.4/3.2 4.4/4.5 4.5/4.5 .002Platelet count 10^3/uL 283/272 286/292 282.5/269 0.95Blood Counts after G-CSF,
before apheresisWBC count x10^3/uL 47.2/47.1 43.1/45.4 49/47.2 0.61Neutrophil count x10^3/
uL32.4/29.4 28.1/26 34.7/33.7 0.26Platelet count x10^3/uL 255/245 239/237 265.8/240.5 0.62% change of WBC count 792/703 619/595 704/682 0.47Product CountsTotal Nucleated Cell
Count x10^1010.2/9.72 9/8.76 9/8.9 0.24Total CD34 Count x10^8 9.5/7.33 7/5.49 6.4/5.7 0.10%CD34 of TNC 0.9/0.86 0.8/0.81 0.7/0.72 0.11CD34 Count/Kg of
donor weight x 10^610.7/9.1 9.2/7.3 8/7.3 0.16CD34 Count/L of blood
processed x 10^647.8/38.2 36.5/31.5 32/28.7 0.08* P-Values were obtained from the comparison between African Amer-
ican donors and Caucasian donors by two sided t-testHISTOCOMPATIBILITY/ALTERNATIVE STEM
CELL SOURCES
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INTRAVENOUS BUSULFAN/FLUDARABINE-BASED CONDITIONING REGI-
MEN IS A FEASIBLE AND EFFECTIVE OPTION IN UNRELATED CORD
BLOOD TRANSPLANTATION
Yamamoto, H.1, Uchida, N.1, Ishiwata, K.1, Nakano, N.1, Tsuji, M.1,
Araoka, H.2, Mori-Asano, Y.1, Wake, A.1, Yoneyama, A.2,
Makino, S.3, Taniguchi, S.1 1Toranomon Hospital, Tokyo, Japan; 2Tor-
anomon Hospital, Tokyo, Japan; 3Toranomon Hospital, Tokyo, Japan
Intravenous busulfan and fludarabine (ivBu + Flu) has been
widely used as preparative regimen in the setting of bone marrow
or peripheral blood stem cell transplantation. In the context of un-
related cord blood transplantation (UCBT), high rate of graft fail-
ure with using ivBU + Flu regimen has been reported, thus the
optimal use of the regimen has not been established. In order to
address this issue, we retrospectively reviewed patients who under-
went UCBT with ivBU + Flu-based conditioning regimens. 49 pa-
tients, who were at ECOG performance status of 2 or less and
received UCBT at our institute from February 2007 to August
2009 consecutively, were included in this study. Median age was
59 years (range, 21-72). 42 were AML/MDS, 5 were ALL, 1
was ATL, and 1 was CML. 44 patients (89.7%) were not in remis-sion, and 13 had history of prior transplantation. Fludarabine 125-
180 mg/m2 and ivBu 6.4-12.8 mg/kg were used in all patients. All
patients received additional melphalan (Mel) or total body irradi-
ation (TBI); Mel 80-140 mg/m2 for 18 and 2-8 Gy of TBI for 31.
Graft-versus- host disease prophylaxis consisted of tacrolimus plus
mycophenolate mofetil in 39 and tacrolimus alone in 10. Single
cord blood units, matched at 4/6 in 42 and 5/6 in 7, of 2 
107/kg of recipient body weight at minimum were infused.
Thirty-seven achieved neutrophil recovery on median-day 21
(range, 13-52) post-transplant. Among 12 who failed to achieve
neutrophil recovery, 5 experienced early disease progression, 4
showed rejection, and 3 died before engraftment due to infections.
All 37 patients who achieved neutrophil engraftment showed com-
plete donor-type chimerism on median-day 14 (range, 8-35) post-
transplant. Median follow-up time of survivors was 375 days
(range, 43-958) post-transplant. Cumulative incidence of non-re-
lapse mortality (NRM) at day 100 and day 365 post-transplant
were 16.4% and 26.9%, respectively. No VOD/SOS was ob-
served. Overall survival (OS) and disease-free survival (DFS)
were 52.2% and 39.5% at 1 year, and 30.7% and 23.7% at 2years,
respectively. The results suggest that, by adding Mel or TBI, iv-
BU + Flu regimen has potential to achieve successful engraftment
of unrelated cord blood graft as well as sufficient disease control
while reducing early NRM. The optimal dosing schedule or com-
bination with other therapeutic modalities needs further investiga-
tion in prospective clinical trials.155
SIMILAR OUTCOMES IN ADULTS AND CHILDREN UNDERGOING FAMILY
HLA-MISMATCHED/HAPLOIDENTICAL HEMATOPOIETIC CELL TRANS-
PLANTATION (HCT)
Dong, L.1, Wu, T.2, Gao, Z.1, Zhang, M.-J.3, Kan, F.4, Spellman, S.R.4,
Zhao, Y.-L.2, Wang, J.-B.2, Tan, X.-Z.1, Lu, D.-P.2, Miklos, D.5,
Petersdorf, E.6, Fernandez-Vina, M.7, Lee, S.J.6 1Dao-Pei Hospital,
Shanghai, China; 2Dao-Pei Hospital, Beijing, China; 3CIBMTR, Mil-
waukee, WI; 4National Marrow Donor Program, Minneapolis, MN;
5Stanford University, Stanford, CA; 6Fred Hutchinson cancer Research
Center, Seattle, WA; 7M.D. Anderson Cancer Center, Houston, TX
Objective: Haploidentical HCT can achieve nearly comparable
therapeutic effects with HLAmatched sibling HCT and may induce
more potent graft-versus-tumor effects. We tested whether the out-
comes for adults and children were different in haploidentical HCT
and sought predictors of HCT success.
Patients: Patients (pts) aged 1-65 yrs receiving myeloablative condi-
tioning regimens with 2 to 3 antigenHLA-mismatched family mem-
ber donors between 2000 and 2005 were included. 137 pts (50
children and 87 adults) were reported to CIBMTR and 181 pts (68
children and 113 adults) were from Dao-Pei Hospital in China.
The CIBMTR cohort was 53% AML, 31% ALL, 9% CML, and
7%MDS, with 26% early, 24% intermediate and 50% advanced dis-
ease. More than 80% of adults and children received either ATG or
in vitro T cell depletion (TCD). Median FU of survivors was 40
months for children and 38 months for adults. In the Chinese cohort
there were 31% AML, 35% ALL, 28% CML, and 6% MDS with
48% early, 27% intermediate and 25% with advanced disease. All
pts received ATG before HCT. Median FU of survivors was 49
months for children and 47 months for adults.
Results: In univariate analyses, 3 year survival in children and adults
was 19 (95% CI [8-32])% and 24 [15-35]% in the CIBMTR cohort,
p5NS and 54 [43-66]% and 53 [44-62]% in the Chinese cohort,
p5NS, respectively. CIBMTRandChinese data were analyzed sep-
arately because of differences in outcomes and pt and HCT charac-
teristics. In the CIBMTR cohort, four subgroups were compared
(Adult-No TCD; Child-No TCD; Adult-TCD, Child-TCD) due
to a significant interaction between age and TCD. With TCD,
adults had a higher mortality rate than children (RR 1.75, [1.08-
2.84], p5 0.023). However, that age effect was not observed in pts
without TCD. Disease stage was also predictive of survival
(p\0.001). In the Chinese cohort, Karnofsky score$90 was associ-
ated with better survival (RR 0.35, [0.22-0.54], p\0.001) as well as
lower TRM, lower relapse and higher DFS. No significant
S216 Poster Session Idifferences were found between children and adults inTRM, relapse,
DFS or survival.
Conclusion:Our results suggest that adults and children have sim-
ilar outcomes after haplo-identical HCT. In vitro TCD in adults is
associated with worse outcomes in the cohort reported to
CIBMTR. Other prognostic factors such as advanced disease stage
in the CIBMTR cohort and Karnofsky score in the Chinese cohort
are consistent with those identified in studies of HLA-matched
donors.156
UNRELATED CORD BLOOD TRANSPLANTATION (UCBT) USING MYELOA-
BLATIVE AND NON-MYELOABLATIVE CONDITIONING FOR 38 PATIENTS
WITH ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
Nakano, N., Wake, A., Yamamoto, H., Shimazu, H., Ishiwata, K.,
Tuji, M., Mori-Asano, Y., Uchida, N., Yoneyama, A., Makino, S.,
Taniguchi, S. Toranomon Hospital, Tokyo, Japan
Aims: The aims of this study are to identify the clinical characteris-
tics and outcomes after uCBT for adult ALL patients.
Patients and Methods: There were 38 ALL patients (22 male, 16
female) who have undergone uCBT between February 2003 and Jan-
uary 2009 consecutively in our institute.We retrospectively analyzed
patients’ clinical characteristics, overall survival (OS), event-free sur-
vival (EFS), leukemia-free survival (LFS) after transplantation, and
these related factors.
Results:Median age was 51.5 yrs (18-68). Disease status at trans-
plantation were 8 patients in CR1, 10 advanced CR and 20 non-
CR. Ph positive patients were 14 and negative 24. Myeloablative
conditioning (MAC) regimens were used in 11 patients (all
TBI12 Gy/CY60 mg/kg based and 3 patients used additional
drugs such as VP16 and cytarabine), and 27 reduced intensity
(RIC) (mainly Flu125-180 mg/m2/Mel80-140 mg/m2/TBI4-8 Gy,
Flu180 mg/m2/BU6.4-8 mg/kg/TBI4-8 Gy based). Thirty patients
obtained engraftment. Median time to engraftment was 20.5 days
(11-56) after transplantation. Twenty-six patients died (11 disease
progression, 8 pneumonia, 3 sepsis, 2 diffuse alveolar hemorrhage,
1 acute GVHD and 1 MOF) and 18 relapsed after transplantation.
Twenty-seven patients had pre-engraftment immune reaction
(PIR), and 22 acute GVHD. Cumulative incidence of non-relapse
mortality (NRM) at day 100 after transplantation was 21.7%.
Two-year OS, EFS and LFS for all patients were 41.5%, 32.9%
and 33.9% respectively. Two-year OS of patients status in CR1,
advanced CR and non-CR at the transplantation were 50%,
50% and 17.1% respectively. Also 2-year OS, EFS of patients
with MAC and RIC were 39.8% vs 42.3% and 36.4% vs 33.8%
respectively. In univariate analysis, significant positive factors con-
tribute to OS, EFS, LFS were PIR. Use of additional drugs in
TBI/CY group showed significantly negative contribution to OS
and EFS.
Conclusions:We conclude that uCBT was feasible treatment for
the adult patients with ALL. Our results suggested no significant
differences between MAC regimen and RIC in uCBT for adult
ALL.157
MOTHER-BABY PARAMETERS IMPACT ON TNC AND CD34 + COUNTS IN
UMBILICAL CORD BLOOD BANKING
Villanueva, C., Pando, J., Saenz, P., Rios, H., Marquez, M., Honda, I.,
Aranda, I., Perez, I., Vidal, G., Huamani, J., Obregon-Zegarra, E.H.,
Carrasco, P., Vidurrizaga, M., Castillo-Aguirre, J., Carrasco-
Yalan, A.A. Criocord, Lima, Peru
Introduction: Umbilical cord blood (UCB) has become an eas-
ily, available and viable source of hematopoeitic SC for trans-
plant. The main limitation factor for its wide use is cell dose.
Previous studies had showed that certain physiological parame-
ters pertaining to the baby or the mother impact in the UCB
cell yields.Objectives: The aim of our study was to compare five physiological
parameters: mothers age [MA], gestational age at delivery [GA], gen-
der [G], birth weight [BW] and type of delivery [TD], comparing
with TNC and CD34 + cells recovery. We also evaluated the impact
of time from collection to processing (TCP) on CD45+ cells
viability.
Results: From May 2004 to Jun 2009, a total of 4262 UCB collec-
tions were performed. 77.87% were collected after cesarean; median
TCP was 30 hours 58 minutes. The mean CBU volume and TNC
count were 81.8 ml and 8.63  108 respectively. The colected vol-
ume was greater in cesarean delivery than vaginal delivery
(F5 30.82, p\0.001). TNC counts collected were directly corre-
lated with GA: in preterm delivery (\37sem) was 7.13108 and in
term delivery ($37sem) was 9.93108 and with BW (F5 325,
p\0.001) while the MA had inverse correlation (F5 8.05,
p5 0.005); regarding TD there was a significant mayor TNC count
in the vaginal vs. cesarean group (10.49108 vs. 9.22108,
F5 48.207, p\0.001); while it was a trend for major TNC count
in females vs. males babies (9.82108 vs. 9.13108, p5 0.059).
CD34+ cells count was directly correlated with BW (F5 70.1,
p\0.001). The strongest correlation was with GA (in preterm:
61.99 CD34+/ul and in term delivery: 84.67 CD34+/ul,
F5 27.62 p5\0.001); Moreover, there was association between
CD34+ cells count with TD (vaginal: 87.88 CD34+/ul vs cesarean:
80.26 CD34+/ul, F5 5.327 p5 0.02). There was not association ei-
ther with G (females: 79.97 CD34+/ul vs males: 83.48 CD34+/ul,
F5 1.668 p5 0.197) neither MA (F5 1.82, p5 0.177). There was
a significant difference between CD34+ viability cells among CBU
with less than 48 hours or more of TCP (99.6% vs. 99.4%,
p5 0.019); this difference was stronger when the CD45+ viability
was evaluated (93.35% vs. 90.14%, p\0,001).
Conclusions: TNC and CD34 +UCB cells are influenced by vari-
ables related to the mother -baby. It looks like on time female babies
with good weight, born to a younger mother and from a vaginal de-
livery reach highest TNCcount. CD34+ cells count was directly cor-
related with BW and CD34+ viability is mainly influenced by the
TCP.158
EFFECTS OF OBSTETRIC FACTORS ON WEIGHTS AND CELL COUNTS OF
CORD BLOOD UNITS
Platz, A.1, Schmidt, A.H.1,2, Aurich, A.-C.1, Solloch, U.V.2, Rutt, C.2,
Ehninger, G.3 1DKMS Lifeline Cord Blood Bank, Dresden, Germany;
2DKMS German Bone Marrow Donor Center, Tuebingen, Germany;
3University Hospital Carl Gustav Carus, Dresden, Germany
High cord blood unit (CBU) cell counts influence the outcome of
cord blood transplantation positively. Therefore, the identification
of obstetric factors that determine CBU cell counts is relevant for
cord blood bank operations.
We quantified weights and white blood cells per volume (WBC,
109/l) and per CBU (TNC, 108) of 206 consecutive CBUs with min-
imum weight 50 g that were sent to DKMS Lifeline Cord Blood
Bank from April to June 2009. The effect of 6 obstetric factors
(baby’s gender and birthweight,mother’s age at delivery and number
of previous pregnancies, gestational age, and birth route) on these
quantities was analyzed.
In univariate analysis, the following effects were significant (t tests,
p\0.05): High birth weight (.3500 g) and gestational age (.40
weeks) were associated with increased WBC (12.1 versus 10.5 and
12.4 versus 10.7, respectively) and TNC (11.2 versus 9.2 and 11.3
versus 9.5, respectively), higher age of mother ($31 years) correlated
with higher CBU weight (80.8 g versus 74.5 g), and vaginal delivery
was associated with higher WBC (12.8 versus 9.0) and TNC (11.3
versus 8.5) and lower CBU weight (75.3 g versus 81.7 g). Besides,
there was a trend to higher CBUweight in male babies (79.9 g versus
74.6 g) but differences were not significant (p5 0.06).
In multiple linear regression analysis, birth weight and birth route
were the only factors that significantly influenced CBU weight,
WBC, or TNC (p\0.05). High birth weight was associated with
high CBU weight (b5 0.22), high WBC (b5 0.20), and high
TNC (b5 0.26). Vaginal delivery correlated with low CBU weight
(b5-0.18), high WBC (b5 0.43), and high TNC (b50.20). Beta
values indicate standardized regression coefficients.
